Helmholtz Gemeinschaft


Pathology of ovarian cancers in BRCA1 and BRCA2 carriers

Item Type:Article
Title:Pathology of ovarian cancers in BRCA1 and BRCA2 carriers
Creators Name:Lakhani, S.R. and Manek, S. and Penault-Llorca, F. and Flanagan, A. and Arnout, L. and Merrett, S. and McGuffog, L. and Steele, D. and Devilee, P. and Klijn, J.G. and Meijers-Heijboer, H. and Radice, P. and Pilotti, S. and Nevanlinna, H. and Butzow, R. and Sobol, H. and Jacquemier, J. and Lyonet, D.S. and Neuhausen, S.L. and Weber, B. and Wagner, T. and Winqvist, R. and Bignon, Y.J. and Monti, F. and Schmitt, F. and Lenoir, G. and Seitz, S. and Hamman, U. and Pharoah, P. and Lane, G. and Ponder, B. and Bishop, D.T. and Easton, D.F.
Abstract:PURPOSE: Germline mutations in the BRCA1 and BRCA2 genes confer increased susceptibility to ovarian cancer. There is evidence that tumors in carriers may exhibit a distinct distribution of pathological features, but previous studies on the pathology of such tumors have been small. Our aim was to evaluate the morphologies and immunophenotypes in a large cohort of patients with familial ovarian cancer. EXPERIMENTAL DESIGN: We performed a systematic review of ovarian tumors from 178 BRCA1 mutation carriers, 29 BRCA2 mutation carriers, and 235 controls with a similar age distribution. Tumors were evaluated by four pathologists blinded to mutation status. Both morphological features and immunochemical staining for p53 and HER2 were evaluated. RESULTS: Tumors in BRCA1 mutation carriers were more likely than tumors in age-matched controls to be invasive serous adenocarcinomas (odds ratio, 1.84; 95% confidence interval, 1.21-2.79) and unlikely to be borderline or mucinous tumors. Tumors in BRCA1 carriers were of higher grade (P < 0.0001), had a higher percentage solid component (P = 0.001), and were more likely to stain strongly for p53 (P = 0.018). The distribution of pathological features in BRCA2 carriers was similar to that in BRCA1 carriers. CONCLUSIONS: Use of pathological features can substantially improve the targeting of predictive genetic testing. Results also suggest that BRCA1 and BRCA2 tumors are relatively aggressive and may be expected to have poor prognosis, although this may be treatment dependent.
Keywords:BRCA2 Protein, Cohort Studies, DNA Mutational Analysis, Disease Progression, BRCA1 Genes, Genetic Predisposition to Disease, Germ-Line Mutation, Heterozygote, Immunohistochemistry, Immunophenotyping, Logistic Models, Middle Aged, Mutation, Odds Ratio, Ovarian Neoplasms, Prognosis, erbB-2 Receptor, Tumor Suppressor Protein p53
Source:Clinical Cancer Research
Publisher:American Association for Cancer Research (U.S.A.)
Page Range:2473-2481
Date:1 April 2004
Official Publication:http://clincancerres.aacrjournals.org/cgi/content/abstract/10/7/2473
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library